Background BRCA1 methylation has been associated with homologous recombination
deficiency, a biomarker of platinum sensitivity. Studies evaluating BRCA1-methylated tubal …

Background In Germany, 17–23% of the population suffers from chronic itching of the skin; in
5–10% of cases, the female genitalia are affected, specifically, the vulva. Vulvar pruritus is …

Background Identification of families at risk for ovarian cancer offers the opportunity to
consider prophylactic surgery thus reducing ovarian cancer mortality. So far, identification of …

Squamous cell carcinoma of the vulva is a rare disease, accounting for approximately 5% of
cancers of the female genital tract. Standard therapy for early-stage vulvar cancer mainly …

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in
cancer cells while sparing normal tissues. Despite promising preclinical results, few patients …

Background Cancer patients are at risk of secondary therapy–related myeloid neoplasms (t-
MNs). Acquired blood-specific mutations in clonal hematopoiesis (CH)–associated genes …

Objective Metastatic vulvar cancer is a rare disease. Information on metastatic patterns and
corresponding prognosis or therapeutic approaches is scarce. We therefore analyzed …

Background For individuals with ovarian cancer (OC), therapy options mainly depend on
BRCA1/2 germline status. What is the prevalence of deleterious somatic variants, that is …

Circulating tumor cells (CTCs) are promising tools for risk prediction and the monitoring of
response to therapy in cancer patients. Within the EU/IMI CANCER-ID consortium, we …

Background In patients with primary vulvar cancer and bilateral sentinel lymph node (SLN)
biopsy, bilateral complete inguino-femoral lymphadenectomy (LAE) is recommended, even …